Immunitas Therapeutics Inc., a company leveraging single cell analysis to identify and validate new drug targets, has closed $58 million in series B financing led by Agent Capital. The funds will be used to advance its lead program, the CD161 inhibitor IMT-009, into the clinic for testing against both solid tumors and hematological malignancies, pending approval of a forthcoming IND filing next year.
The research challenge facing the scientific founders of newly launched Immunitas Therapeutics Inc. was getting human samples to deeply analyze in their quest to understand autoimmunity. While the research continued slowly, the science raced ahead.